BioSpace News Archive

Business

Fibrocor and Galapagos sign partnership in fibrosis

Fibrocor Therapeutics L.P. and Galapagos NV announced a global partnership focused on a novel target for idiopathic pulmonary fibrosis (IPF) and other indications.

January 7, 2019
·
5 min read
Business

BioSpace Hotbed Report: A Look at the Life Science Industry in the City by the Bay

With more than 82,500 employees working in the sector, California’s Bay Area is one of the strongest homes for biotech companies in the world.

January 7, 2019
·
3 min read
·
Alex Keown
Drug Development

Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis

Galapagos NV expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with ‘1690 in IPF.

January 7, 2019
·
5 min read
Epigenomics AG Announces Positive Results from Microsimulation Model

January 7, 2019
·
2 min read
Policy

Achievement of two major development milestones

IDE application submitted to the FDA for HEMOSNOWTM

January 7, 2019
·
4 min read
Business

Adaptive Biotechnologies and Genentech Launch Personalized Cancer-Care Program Worth $2 Billion+

Seattle-based Adaptive Biotechnologies forged a collaboration with Genentech that could be worth up to $2 billion to develop and commercialize novel neoantigen directed T-cell therapies for the individualized treatment of a broad range of cancers.

January 7, 2019
·
3 min read
·
Alex Keown
Business

Executive Women In Bio Releases First Annual Directory of Boardroom Ready Executive Profiles

Applications for the 2019 Boardroom Ready program now open

January 7, 2019
·
3 min read
Business

Gilead Inks $785 Million Deal With Yuhan for NASH Development

Gilead Sciences is acquiring the global rights to develop and commercialize novel small molecules against two targets from Yuhan Corporation, based in South Korea. They drugs will be developed to treat advanced fibrosis related to nonalcoholic steatohepatitis (NASH).

January 7, 2019
·
3 min read
·
Mark Terry
Drug Development

Galapagos starts first Phase 1 trial with Toledo compound

Novel target class with dual action in inflammatory disorders

January 7, 2019
·
4 min read
Deals

Eli Lilly Deepens Its Oncology Offerings With an $8 Billion Acquisition of Loxo Oncology

Eli Lilly and Company announced it was buying Loxo Oncology for $235 per share in cash, which comes to about $8 billion. The acquisition adds a lot of weight to Lilly’s oncology efforts.

January 7, 2019
·
3 min read
·
Mark Terry